Dementia and Exercise

Johns Hopkins Health Alert

Research on Vascular Dementia and Exercise

Comments (0)

Mental decline in older adults who live independently can be delayed if they get regular physical activity, says a new study. Specifically, the study reports that exercise can reduce the risk of vascular-related dementia by more than 50 percent and cognitive impairment without dementia by 60 percent.

Vascular dementia results from blood vessel disease and is associated with conditions like high blood pressure, plaque buildup in artery walls, diabetes and stroke.

The study, which was reported in the online edition of Stroke, followed 638 people, average age of 74, for three years. Sixty-four percent said they were physically active 30 minutes a day for three days a week.

Their activities involved walking, biking and taking gym classes. The results were disappointing, however, when it came to protecting against Alzheimer's. Researchers found no relationship between activity and the risk of developing Alzheimer's.  

Posted in Memory on July 22, 2013

Your Road Map to the Future Begins Here

Alzheimer's Outlook 2013

Eight leading experts provide the latest thinking on new and emerging approaches to the prevention, diagnosis and treatment of Alzheimer's disease and other dementias

* * * * * * * * * * * * * * *

If you or a loved one has been diagnosed with Alzheimer's disease or another memory disorder...

Or if you are caring for someone with Alzheimer's and are wondering if there's a new drug or therapy in the pipeline that might help...

Then it's vitally important to stay on top of developments in the field -- so you can ask your doctor the key questions -- and discuss the critical issues that affect the management of the disease.

To help you, we have just published Alzheimer's Outlook 2013 -- a valuable new resource that allows you to sit down with a group of preeminent physicians and listen in as they share their insights and ideas about the future course of Alzheimer's disease -- and provide a clear sense of what caregivers and patients can hope for.

Alzheimer's Outlook 2013 is part of a series of annual research reports written for concerned lay readers. It gives you special access to information you won't find anywhere else on the future of Alzheimer's research.

What's in the Alzheimer's pipeline?

In the past few years, researchers have made meaningful strides in the understanding of dementia prevention, diagnosis and treatment. Many important breakthroughs have come from the talented physicians and scientists working here at Johns Hopkins Medicine.

In the pages of Alzheimer's Outlook 2013 you'll gain unprecedented access to the insights of Hopkins experts, as well as from colleagues at other renowned research centers.

And there's so much exciting information to report!

Although we don't yet have a drug to stop the disease progression, new techniques in molecular biology and genetics are providing remarkable insights into how and why Alzheimer's begins, how it progresses and how it produces symptoms.

Great progress has also been made in brain imaging and other biomarkers that might allow us to diagnose Alzheimer's when no or minimal symptoms are present.

Here's a sample of other key highlights in Alzheimer's Outlook 2013:

• Two key strategies to help you maintain optimal brain health by Marilyn S. Albert, Ph.D., Professor of Neurology and Director of the Division of Cognitive Neuroscience at Johns Hopkins Medicine.
• Early findings from the ADvance Study, which uses deep brain stimulation on patients in the early stages of Alzheimer's disease by Peter V. Rabins, M.D., M.P.H., Professor of Psychiatry at Johns Hopkins and Medical Editor of the Johns Hopkins Memory Disorders Bulletin.
• What we've learned about dementia and healthy aging from studying the oldest-old: Findings from the 90+ Study by Claudia H. Kawas, M.D., Professor of Neurology and Neurobiology and Behaviors at the University of California, Irvine and principal investigator for the 90+ Study.
• Update: Drugs in development that affect beta-amyloid and tau by Donald Price, M.D., Professor of Pathology, Neurology and Neuroscience at Johns Hopkins.
• A close look at tau aggregation, Braak staging and dementia symptoms by Claude Wischik, M.D., Ph.D., Professor of Old Age Psychiatry, University of Aberdeen and co-founder of TauRX Pharmaceuticals Ltd.
• The DIAN Study (Dominantly Inherited Alzheimer's Network), a pioneering multi-site prevention study which will test three drugs on the brains of people who have inherited mutations known to cause early-onset Alzheimer's disease by John C. Morris, M.D., Friedman Distinguished Professor of Neurology at Washington University School of Medicine.
• Preventing Alzheimer's disease: The API Study by Pierre N. Tariot, M.D., Director of the Banner Alzheimer's Institute Memory Disorders Center in Phoenix, Arizona.
• The A4 Trial, recently approved by the National Institutes of Health, which will track the cognitive health of patients who are currently asymptomatic but who have a high chance of developing Alzheimer's by Reisa Sperling, M.D., M.MSc., Director of the Center for Alzheimer's Research and Treatment at Brigham and Women's Hospital in Boston.

* * * * * * * * * * * * * * *

As we mentioned, Alzheimer's Outlook 2013 is part of a series of annual research updates on Alzheimer's and related dementias. As a buyer of this year's edition, you'll be among the first to be notified when the 2014 edition is published next year.

This is information so critical to being an informed patient that we want you to have it right away. We've created Alzheimer's Outlook 2013 as an instant PDF download to ensure that you can start reading this material today. You can be sure your copy will contain up-to-the minute information to help stay on top of the latest developments.

Still not sure you'll benefit from this Special Report? No problem.
Our No-Strings, Can't Lose, Must-Be-Satisfied Offer!

Alzheimer's Outlook 2013 comes with a risk-free offer of satisfaction: if you're not satisfied for any reason, simply contact Customer Service within 30 days for a prompt refund of your full purchase price of $29.95 So you risk nothing.